Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.

ABSTRACT: Although most acute myeloid leukemia (AML) patients achieve complete remissions, the majority still eventually relapse and die of their disease. Rare primitive leukemia cells, so-called leukemia stem cells (LSCs), represent one potential type of resistant cell subpopulation responsible for this dissociation between response and cure. Several LSC targets have been described, but there is limited evidence about their relative utility or that targeting any can prevent relapse. LSCs not only appear to be biologically heterogeneous, but the classic immunocompromised mouse transplantation model also has serious shortcomings as an LSC assay. Out data suggest that the most immature cell phenotype that can be identified within a patient's leukemia may be clinically relevant and represent the de fac

SUBMITTER: Yanagisawa B 

PROVIDER: S-EPMC7969493 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature